"What Has Actually Worked for Your Chronic Migraine?" What 2026 Clinical Data Reveals About CGRP Inhibitors

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or changing any migraine treatment.

When someone posts in r/migraine asking what actually works for chronic migraine, the responses typically range from "ice packs and prayer" to exhaustive supplement stacks. But buried in those threads, one treatment category keeps surfacing with striking consistency: CGRP inhibitors. Not the anecdotal enthusiasm that surrounds magnesium or riboflavin, but stories that sound almost unbelievable—people going from 15 or more migraine days per month down to single digits.

These are not isolated experiences. The emergence of calcitonin gene-related peptide (CGRP) monoclonal antibodies has arguably reshaped migraine prevention more dramatically than any pharmaceutical development since the introduction of triptans in the 1990s. And the clinical data released in early 2026 adds new dimensions to what we understand about their effectiveness.

What Is CGRP and Why Target It?

CGRP is a 37-amino acid neuropeptide found throughout the peripheral and central nervous systems. In the context of migraine, its role has been increasingly well-defined through decades of research. During a migraine attack, CGRP levels spike in the trigeminal vascular system—the network of blood vessels and nerves responsible for headache pain. This elevation correlates directly with the intensity and duration of attacks.

The peptide functions as a potent vasodilator and plays a central role in nociception, the nervous system's response to potentially harmful stimuli. In migraine specifically, CGRP appears to facilitate the transmission of pain signals and promote neurogenic inflammation. The theoretical framework is straightforward: block CGRP or its receptor, interrupt the cascade that generates and sustains migraine attacks.

What distinguishes CGRP-targeting therapies from older preventive medications is specificity. Traditional preventives—beta blockers, anticonvulsants, tricyclic antidepressants—were borrowed from other medical specialties based on observational efficacy. Their mechanisms in migraine were poorly understood, and side effect profiles reflected their non-specific actions. A medication designed for blood pressure reduction will inevitably cause blood pressure-related side effects, even when prescribed for headache prevention.

The Four CGRP Monoclonal Antibodies: A Comparative Overview

Four CGRP monoclonal antibodies have received FDA approval for migraine prevention. They divide into two mechanistic categories: those targeting the CGRP ligand itself (Aimovig, Ajovy, Emgality) and those targeting the CGRP receptor (Vyepti). Understanding this distinction matters because it partially explains differences in efficacy and side effect profiles.

Aimovig (Erenumab)

Developed by Amgen and Novartis, Aimovig was the first CGRP inhibitor to reach the market, receiving FDA approval in May 2018. It is the only monoclonal antibody that targets the CGRP receptor rather than the ligand. Available in monthly subcutaneous injections of 70 mg or 140 mg, Aimovig established the proof-of-concept for this entire drug class.

Clinical trial data demonstrated that approximately 56% of patients achieved at least a 50% reduction in monthly migraine days at the 70 mg dose, with the 140 mg dose pushing that figure to approximately 60%. For chronic migraine patients—those experiencing 15 or more headache days per month—these represent clinically transformative outcomes.

Ajovy (Fremanezumab)

Teva's Ajovy offers greater dosing flexibility than its competitors. Patients can choose between monthly injections (225 mg) or quarterly injections (675 mg), a distinction that matters substantially for adherence and quality of life. The January 2026 publication of the SPACE trial in the New England Journal of Medicine expanded Ajovy's indications to include pediatric patients aged 6-17 years weighing at least 45 kilograms.

The SPACE trial data represents a significant milestone. In this randomized, double-blind, placebo-controlled study of 237 children and adolescents with episodic migraine, Ajovy reduced monthly migraine days by 2.5 days compared to 1.4 days with placebo—a statistically significant difference of 1.1 days. Critically, 47.2% of participants achieved at least a 50% reduction in monthly migraine days versus 27.0% in the placebo group.

For pediatric migraine—historically underserved with FDA-approved preventive options—these results matter enormously. Migraine in children and adolescents correlates with missed school days, impaired educational performance, and significant impacts on social development.

Emgality (Galcanezumab)

Eli Lilly's Emgality shares the monthly dosing schedule of Aimovig, administered at 120 mg per month. What distinguishes Emgality in clinical discussions is its additional FDA approval for cluster headache, the most severe primary headache disorder. This dual indication suggests a broader efficacy profile across headache types characterized by trigeminal activation.

Vyepti (Eptinezumab)

Developed by Lundbeck and Alder BioPharmaceuticals, Vyepti is administered intravenously every three months (100 mg or 300 mg). The quarterly infusion schedule appeals to patients who struggle with self-injection or who prefer less frequent medical interactions. Clinical trials demonstrated efficacy comparable to subcutaneous alternatives, with the 300 mg dose showing particular strength in patients with chronic migraine.

What the 2026 Data Actually Shows

The research published in early 2026 has refined our understanding of CGRP inhibitor effectiveness across several dimensions. The SPACE trial mentioned earlier adds pediatric data to what had been an exclusively adult evidence base. But other developments warrant attention.

A comprehensive review published in January 2026 in PMC synthesized real-world evidence alongside clinical trial data. Real-world studies—observational research following patients in actual clinical practice rather than controlled trial conditions—often reveal different patterns than highly selective clinical populations. The convergence of trial data and real-world outcomes strengthens confidence in these medications' practical utility.

The review emphasized that CGRP inhibitors demonstrate consistent efficacy across migraine subtypes: episodic migraine (fewer than 15 headache days monthly), chronic migraine (15 or more), and even medication overuse headache. This broad applicability distinguishes them from many preventive medications that show efficacy in one population but fail in others.

Perhaps most striking is the rapidity of response. Unlike oral preventive medications that may require 8-12 weeks to demonstrate benefit, CGRP inhibitors frequently show measurable effects within the first month of treatment. For patients who have endured months of titration schedules with minimal improvement, this speed matters.

The Side Effect Profile: What Patients Actually Experience

Clinical trials report discontinuation rates due to adverse events below 5% for all four CGRP inhibitors—a remarkably favorable profile compared to traditional preventive medications. The most commonly reported side effects include injection site reactions (erythema, pain, pruritus) and constipation, particularly with receptor-targeting Aimovig.

However, real-world data from 2025-2026 has expanded the conversation about potential adverse effects. Some patients report increased hair shedding, though causality remains difficult to establish given the prevalence of telogen effluvium in the general population. Others describe transient blood pressure elevations, which prompted regulatory attention given the cardiovascular implications of CGRP inhibition.

The cardiovascular question deserves particular scrutiny. CGRP functions as a protective vasodilator; blocking its action theoretically could impair compensatory responses to cardiac ischemia. Long-term cardiovascular outcome data remains limited, though observational studies to date have not demonstrated increased cardiovascular events in treated populations. The FDA continues to monitor this signal through post-marketing surveillance.

Practical Considerations: Access, Cost, and Selection

Despite the clinical enthusiasm surrounding CGRP inhibitors, significant barriers to access persist. Without insurance coverage, these medications cost approximately $600-700 per month—prohibitively expensive for most patients. The manufacturers offer patient assistance programs, but navigating these requires persistence and often physician office support.

Insurance coverage has improved since initial approvals, though prior authorization requirements remain common. Most insurers require documented failure of at least two oral preventive medications before approving CGRP inhibitors, reflecting cost-containment priorities rather than clinical reasoning. For patients who have already endured multiple failed medication trials, this hurdle may be surmountable. For others, it represents additional months of preventable suffering.

Selection among the four available options involves considerations beyond pure efficacy data. Injection frequency preference, history of constipation (favoring ligand-targeting options over Aimovig for susceptible patients), comorbid cluster headache (favoring Emgality), and pediatric status (now favoring Ajovy) all inform individualized decision-making.

Limitations and Unanswered Questions

Intellectual honesty requires acknowledging what CGRP inhibitors do not accomplish. These are preventive medications, not abortive treatments. They reduce attack frequency and severity but do not eliminate migraine entirely for most patients. Breakthrough attacks still require acute management with triptans, NSAIDs, or the newer gepant class of acute medications (Ubrelvy, Nurtec, Qulipta).

Approximately 30-40% of patients do not achieve the 50% response threshold typically defined as clinically meaningful. This non-response rate, while lower than many traditional preventives, means CGRP inhibitors represent one component of a broader therapeutic arsenal rather than a universal solution.

The optimal treatment duration also remains uncertain. Unlike antibiotics with defined courses, CGRP inhibitors are approved for indefinite preventive use. Whether patients can eventually discontinue therapy while maintaining benefit, or whether prolonged exposure produces diminishing returns, has not been established through long-term controlled trials.

Integration with Lifestyle and Complementary Approaches

CGRP inhibitors do not exist in isolation from broader migraine management strategies. The most successful patients typically combine pharmacological prevention with trigger management, sleep hygiene optimization, and stress reduction techniques. The medication reduces the brain's susceptibility to migraine activation; lifestyle modifications reduce the frequency of triggering stimuli.

Some evidence suggests additive benefits when CGRP inhibitors are combined with nutraceutical approaches like magnesium supplementation or coenzyme Q10, though rigorous trial data examining these combinations specifically remains limited. The biologically plausible mechanism—CGRP inhibition plus metabolic support—has intuitive appeal, but clinical validation would strengthen recommendations.

So What Actually Works?

Returning to the Reddit question that initiated this exploration—what has actually worked for chronic migraine?—the clinical data supports a nuanced answer. For approximately 50-60% of patients, CGRP monoclonal antibodies produce meaningful reductions in attack frequency and severity. For a subset of these responders, the transformation approaches life-changing: from disability to functionality, from monthly crises to manageable inconvenience.

But these medications are not miracle cures. They require appropriate patient selection, realistic expectation-setting, persistence through insurance navigation, and integration with broader management strategies. The side effect profile, while favorable compared to alternatives, is not zero.

What distinguishes CGRP inhibitors from the supplement stacks and unproven interventions that populate migraine forums is the strength of evidence supporting their use. Multiple large randomized controlled trials, real-world effectiveness studies, and now expanding pediatric data provide a foundation of confidence that most alternative approaches lack.

For chronic migraine patients who have cycled through beta blockers, anticonvulsants, and antidepressants without adequate benefit, CGRP inhibitors represent a genuinely different therapeutic mechanism—and for many, a genuinely different outcome.

Sources

1. Hershey AD, et al. Fremanezumab for Episodic Migraine in Children and Adolescents. New England Journal of Medicine. Published January 14, 2026.
2. Teva Pharmaceutical Industries Ltd. AJOVY FDA Approval for Pediatric Migraine Prevention. August 2025.
3. CGRP and Migraine: Real World Insights and Future Therapeutic Perspectives. PMC. January 21, 2026.
4. Cleveland Clinic. CGRP Inhibitors: What They Are, Uses & Side Effects. January 2025.
5. Migraine Canada. CGRP Monoclonal Antibodies (MABs): Summary and Effectiveness. 2026.
6. Drugs.com. CGRP Inhibitors & Antagonist Drugs List. May 2024.